文献速递胃肠动力与功能性疾病

综述:功能性消化不良的治疗选择

Review article: treatment options for functional dyspepsia.
PubMed 文献 · Aliment Pharmacol Ther · 2019-03-28

本文综述功能性消化不良的药物与非药物治疗选项。检索Pubmed等来源的相关研究。抑酸治疗可使30%-70%患者症状减轻,幽门螺杆菌根除在感染患者中有效率为24%-82%,神经调节剂症状缓解率为27%-71%,针灸、认知行为疗法和催眠疗法可能有助于控制症状但研究稀疏。

要点

  • 抑酸治疗可使30%-70%的功能性消化不良患者症状减轻,质子泵抑制剂优于H2受体拮抗剂。
  • 幽门螺杆菌根除推荐用于感染患者,有效率为24%-82%。
  • 神经调节剂用于难治性症状,症状缓解率为27%-71%,但疗效尚未完全阐明。

核心结论

  • 现有治疗均不能对多数患者有效而不伴明显副作用。
  • 功能性消化不良的异质性、缺乏易识别的靶机制及病理生理紊乱与症状关联差使新治疗开发具有挑战性。

研究设计与样本

  • 在Pubmed及其他来源进行文献检索以识别相关研究。

主要发现

  • 抑酸治疗使30%-70%的患者症状减轻,在餐后不适综合征中获益更高,质子泵抑制剂疗效优于H2受体拮抗剂。
  • 促动力药主要用于治疗餐后不适综合征,多巴胺受体拮抗剂应答率为59%-81%,5-羟色胺4受体激动剂为32%-91%,毒蕈碱受体拮抗剂为31%-80%。
  • 幽门螺杆菌根除推荐用于感染患者,有效率为24%-82%。
  • 神经调节剂用于难治性症状,症状缓解率为27%-71%,但其在功能性消化不良中的疗效尚未完全阐明。
  • 薄荷油使66%-91%的患者症状减轻,六君子汤为29%-34%,Iberogast为20%-95%。

关键数值与推荐

  • 抑酸治疗症状减轻率30%-70%。
  • 多巴胺受体拮抗剂应答率59%-81%。
  • 5-羟色胺4受体激动剂应答率32%-91%。
  • 毒蕈碱受体拮抗剂应答率31%-80%。
  • 幽门螺杆菌根除有效率24%-82%。

临床怎么用

  • 抑酸治疗可用于功能性消化不良,在餐后不适综合征中获益更高,质子泵抑制剂优于H2受体拮抗剂。
  • 促动力药主要用于治疗餐后不适综合征。
  • 幽门螺杆菌根除推荐用于感染患者。
  • 神经调节剂用于难治性症状。
  • 针灸、认知行为疗法和催眠疗法可能有助于控制症状,但相关研究稀疏。

局限性

  • 功能性消化不良的异质性、缺乏易识别的靶机制及病理生理紊乱与症状关联差使新治疗开发具有挑战性。
  • 针灸、认知行为疗法和催眠疗法的疗效研究稀疏。
  • 神经调节剂在功能性消化不良中的疗效尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Functional dyspepsia, consisting of epigastric pain syndrome and postprandial distress syndrome, is a prevalent functional gastrointestinal disorder. To date, only limited treatment options are available and conflicting results in terms of efficacy have been reported. Consequently, nonpharmacological treatment options are increasingly being explored for functional dyspepsia. AIM: To provide an overview of current pharmacological and nonpharmacological treatment options for functional dyspepsia. METHODS: A literature search was conducted on Pubmed and other sources to identify relevant studies. RESULTS: Acid suppressive therapy reduced symptoms in 30%-70% of the patients, with higher benefit in epigastric pain syndrome and superior effectiveness for proton pump inhibitors compared to H2 -antagonists. Prokinetic agents, primarily used to treat postprandial distress syndrome, showed variable efficiency: 59%-81% responder rate for dopamine receptor antagonists, 32%-91% for serotonin-4-receptor agonists and 31%-80% for muscarinic receptor antagonists. H Pylori eradication, recommended in infected patients, was effective in 24%-82%. Refractory symptoms are addressed with neuromodulators. However, their efficacy in functional dyspepsia remains incompletely elucidated, available data showing symptom reduction in 27%-71% of the patients. Regarding herbal agents, peppermint oil reduced symptoms in 66%-91%, rikkunshito in 29%-34% and iberogast in 20%-95%. Lastly, acupuncture, cognitive behavioural therapy and hypnotherapy may help to provide symptom control, but research on their efficacy remains sparse. CONCLUSIONS: None of the available therapies is effective in the majority of patients without being associated with major side effects. Developing new treatment options is challenging due to the heterogeneity of functional dyspepsia, the lack of readily identified target mechanisms and the poor association between pathophysiological disturbances and symptoms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Masuy I, Van Oudenhove L, Tack J, et al. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther. 2019. PMID: 30924176. doi:10.1111/apt.15191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。